Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Biogen Says Estimated Charge Expected To Impact GAAP & Non-GAAP Net Income Per Diluted Share For Q3 By $(0.01) Per Share; Expects Q3 Results To Include Acquired In-Process R&D, Upfront And Milestone Expense Of About $2M On Pre-Tax Basis

Author: Benzinga Newsdesk | October 14, 2025 03:23pm

- SEC Filing

Posted In: BIIB